|
14 Oct 2020 |
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma
|
|
14 Oct 2020 |
SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery
|
|
13 Oct 2020 |
Nuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas
|
|
13 Oct 2020 |
Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer
|
|
13 Oct 2020 |
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
|
|
13 Oct 2020 |
Phase 2b/3 trial shows efficacy of filgotinib for the induction and maintenance of remission in moderately and severely active ulcerative colitis
|
|
13 Oct 2020 |
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
|
|
13 Oct 2020 |
Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients with advanced urothelial cancer
|
|
13 Oct 2020 |
Rappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugs
|
|
12 Oct 2020 |
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
|
|
11 Oct 2020 |
Bristol Myers Squibb Presents Positive Late-Breaking Data from Phase 3 True North Trial Evaluating Zeposia (ozanimod) in Adult Patients with Moderate to Severe Ulcerative Colitis
|
|
10 Oct 2020 |
Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100
|
|
10 Oct 2020 |
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed with TP-1454 in Patients with Advanced Solid Tumors
|
|
10 Oct 2020 |
PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
|
|
10 Oct 2020 |
Sobi announces topline phase 3 data of avatrombopag for the treatment of Chemotherapy-Induced Thrombocytopenia
|
|
09 Oct 2020 |
Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor
|
|
09 Oct 2020 |
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
|
|
09 Oct 2020 |
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
|
|
08 Oct 2020 |
Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
|
|
08 Oct 2020 |
Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
|
|
08 Oct 2020 |
Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
|
|
08 Oct 2020 |
Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified
|
|
07 Oct 2020 |
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
|
|
07 Oct 2020 |
AbFero Announces PK Study Results For SP-420 In Transfusional Iron Overload -- Proceeds With Phase 1-2 Trial Of Iron Chelator
|
|
06 Oct 2020 |
SpringWorks Therapeutics Announces Clinical Collaboration with Pfizer Inc. to Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
|
